Silk Road Medical, Inc. operates as a medical device company in the United States.
Silk Road Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$58.23|
|52 Week High||US$43.11|
|52 Week Low||US$75.80|
|1 Month Change||23.00%|
|3 Month Change||16.76%|
|1 Year Change||-16.35%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||60.95%|
Recent News & Updates
Is There An Opportunity With Silk Road Medical, Inc's (NASDAQ:SILK) 48% Undervaluation?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Silk Road Medical, Inc...
|SILK||US Medical Equipment||US Market|
Return vs Industry: SILK underperformed the US Medical Equipment industry which returned 34.6% over the past year.
Return vs Market: SILK underperformed the US Market which returned 33.8% over the past year.
Stable Share Price: SILK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SILK's weekly volatility (8%) has been stable over the past year.
About the Company
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products includes ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
Is Silk Road Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SILK ($58.23) is trading below our estimate of fair value ($123.47)
Significantly Below Fair Value: SILK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SILK is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SILK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SILK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SILK is overvalued based on its PB Ratio (21x) compared to the US Medical Equipment industry average (4.8x).
How is Silk Road Medical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SILK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: SILK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SILK's is expected to become profitable in the next 3 years.
Revenue vs Market: SILK's revenue (24.6% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: SILK's revenue (24.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SILK is forecast to be unprofitable in 3 years.
How has Silk Road Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SILK is currently unprofitable.
Growing Profit Margin: SILK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SILK is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.
Accelerating Growth: Unable to compare SILK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SILK is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).
Return on Equity
High ROE: SILK has a negative Return on Equity (-50.24%), as it is currently unprofitable.
How is Silk Road Medical's financial position?
Financial Position Analysis
Short Term Liabilities: SILK's short term assets ($158.5M) exceed its short term liabilities ($16.7M).
Long Term Liabilities: SILK's short term assets ($158.5M) exceed its long term liabilities ($55.4M).
Debt to Equity History and Analysis
Debt Level: SILK's debt to equity ratio (50.6%) is considered high.
Reducing Debt: Insufficient data to determine if SILK's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SILK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SILK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Silk Road Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SILK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SILK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SILK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SILK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SILK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Erica Rogers (57 yo)
Ms. Erica J. Rogers serves as the Chief Executive Officer and President of Silk Road Medical Inc since October 2012. Ms. Rogers serves as Independent Director at Sight Sciences, Incorporated since November...
CEO Compensation Analysis
Compensation vs Market: Erica's total compensation ($USD2.16M) is below average for companies of similar size in the US market ($USD3.69M).
Compensation vs Earnings: Erica's compensation has been consistent with company performance over the past year.
Experienced Management: SILK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: SILK's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
Silk Road Medical, Inc's employee growth, exchange listings and data sources
- Name: Silk Road Medical, Inc
- Ticker: SILK
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$2.020b
- Shares outstanding: 34.68m
- Website: https://silkroadmed.com
Number of Employees
- Silk Road Medical, Inc
- 1213 Innsbruck Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:15|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.